Relypsa Announces Topline Results From Patiromer Phase 1 Onset-of-Action Study
GlobeNewswire - Mon May 12, 7:01AM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced topline results from its Phase 1 onset-of-action study of patiromer, the final clinical trial planned to support a New Drug Application (NDA), which the company expects to submit to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014. The study reached its primary endpoint in which an early onset of potassium lowering action was observed. Following the first dose of patiromer, reductions in mean serum potassium were observed at all examined time points, with statistical significance first demonstrated at the second measurement (7 hours post drug administration). Over the 48-hour treatment period, during which patiromer was dosed twice daily, the potassium lowering effect was sustained with a steady decline in mean serum potassium, with no loss of effect or rebound in mean potassium levels during night-time periods.
Relypsa Announces First Quarter 2014 Financial Results
GlobeNewswire - Wed May 07, 3:48PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2014. Net loss for the first quarter 2014 was $16.1 million, or $0.54 per share, compared to $26.3 million, or $84.61 per share, for the comparable period in 2013.
Hypercholesterolemia - Pipeline Review, H1 2014: 22 Company and 41 Drug Profiled
M2 - Wed May 07, 9:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7sxbqm/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Alnylam Pharmaceuticals, Inc. - Amgen Astellas BioPharma K.K. - Bristol-Myers Squibb Company - Catabasis Pharmaceuticals, Inc. - Dybly AG - Eli Lilly and Company - Esperion Therapeutics, Inc. - FORMAC Pharmaceuticals N.V. - Immune Response BioPharma, Inc. - Johnson & Johnson - LondonPharma Ltd - Lumena Pharmaceuticals, Inc. - Madeira Therapeutics - Merck & Co., Inc. - NanoForm Therapeutics Ltd. - Pfizer Inc. - Planet Biotechnology Inc. - Regeneron Pharmaceuticals, Inc. - Relypsa, Inc. - Santaris Pharma A/S - Serometrix, LLC - Zhejiang Hisun Pharmaceutical Co., Ltd. Drug Profiles: - anacetrapib - alirocumab - evolocumab - bococizumab - ETC-1002 - Alpha Cyclodextrin - evolocumab - BMS-770767 - bococizumab - LY-3015014 - CAT-2003 - SPC-4955 - MGL-3196 - ALN-PCS02 - SPC-5001 - BMS-962476 - ralpancizumab - BMS-852927 - fenofibrate - simvastatin - fluvastatin sodium - pravastatin sodium - LUM-002 - PF-06678552 - HS-25 - ALN-PCS02 - RLY-106 - atorvastatin calcium - 1D05-Fab - IR-1002 For more information visit http://www.researchandmarkets.com/research/7s...lesterolem
Relypsa to Present at Bank of America Merrill Lynch 2014 Health Care Conference
GlobeNewswire - Tue May 06, 9:16AM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that John Orwin, Chief Executive Officer, will present a corporate overview at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on May 13, 2014 at 5:00 pm PT.
Relypsa, Inc. Announces Closing of Public Offering of Common Stock
GlobeNewswire - Wed Apr 16, 3:00PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the closing of its public offering of 4,130,611 shares of its common stock at a price to the public of $24.50 per share for gross proceeds of approximately $101 million, which includes the exercise in full by the underwriters of their option to purchase up to 538,775 additional shares of common stock. Relypsa estimates net proceeds from the offering to be approximately $94 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Nasdaq stocks posting largest percentage decreases
AP - Tue Apr 15, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Relypsa, Inc. Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Thu Apr 10, 10:50PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the pricing of an underwritten public offering of 3,591,836 shares of its common stock at a price to the public of $24.50 per share for gross proceeds of approximately $88 million. Relypsa estimates net proceeds from the offering to be approximately $82 million, after deducting underwriting discounts and commissions and estimated offering expenses. In addition, Relypsa has granted the underwriters a 30-day option to purchase up to an additional 538,775 shares of common stock.
Relypsa, Inc. Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Apr 08, 3:05PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of $80 million. All of the shares of the common stock to be sold in the offering will be offered by Relypsa. In addition, Relypsa intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares sold. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Relypsa Names Sylvia R. Wheeler V.P. Investor Relations and Corporate Affairs
GlobeNewswire - Wed Apr 02, 8:43AM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the appointment of Sylvia R. Wheeler to the position of Vice President, Investor Relations and Corporate Affairs. Ms. Wheeler, a veteran biopharmaceutical executive, joins Relypsa with over 20 years of experience in investor relations and corporate communications. In her new role, Ms. Wheeler will be a member of the leadership team and will report to John Orwin, President and Chief Executive Officer of Relypsa.
Weakness Seen in Relypsa (RLYP): Stock Plunges 19.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 7:42AM CDT
Relypsa (RLYP) fell over 19% in the last trading session amid high volumes, breaking its recent volatile trend as it is currently trading below the volatile price range of last one month.
Relypsa (RLYP) in Focus: Stock Adds 12.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 8:46AM CDT
Relypsa was a big mover last session, with shares rising over 12% on the day.
Rev Shark: A Messy Day of Action
at The Street - Wed Mar 19, 3:31PM CDT
A few minor changes to Fed policy were enough to spook the market.
Narrower-Than-Expected Loss at Relypsa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 18, 8:20AM CDT
Relypsa reported a loss of 68 cents per share narrower than the Zacks Consensus Estimate of a loss of 74 cents.
Relypsa Announces Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Mon Mar 17, 3:26PM CDT
Relypsa, Inc. (Nasdaq: RLYP), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2013.